You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromazepam
Accession NumberDB01558
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionOne of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines.
Structure
Thumb
Synonyms
Bromazepamum
Lectopam
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-bromazepam 1.5mg Tabletstablet1.5 mgoralAltimed Pharma Inc.1996-12-312005-05-27Canada
Alti-bromazepam 3mg Tabletstablet3 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-bromazepam 6mg Tabletstablet6 mgoralAltimed Pharma Inc.1996-12-312005-05-27Canada
Bromazepam-1.5 - Tab 1.5mgtablet1.5 mgoralPro Doc Limitee1997-05-202010-07-13Canada
Bromazepam-3 - Tab 3mgtablet3 mgoralPro Doc Limitee1996-12-04Not applicableCanada
Bromazepam-6 - Tab 6mgtablet6 mgoralPro Doc Limitee1996-12-04Not applicableCanada
Gen-bromazepam - Tab 3mgtablet3 mgoralGenpharm Ulc1995-12-312010-08-04Canada
Gen-bromazepam - Tab 6mgtablet6 mgoralGenpharm Ulc1995-12-312010-08-04Canada
Lectopam Tab 1.5mgtablet1.5 mgoralHoffmann La Roche Limited1986-12-312006-07-25Canada
Lectopam Tab 3mgtablet3 mgoralHoffmann La Roche Limited1981-12-31Not applicableCanada
Lectopam Tab 6mgtablet6 mgoralHoffmann La Roche Limited1981-12-31Not applicableCanada
Mylan-bromazepamtablet1.5 mgoralMylan Pharmaceuticals Ulc1995-12-312012-10-19Canada
Nu-bromazepam - Tab 1.5mgtablet1.5 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-bromazepam - Tab 3mgtablet3 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-bromazepam - Tab 6mgtablet6 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Penta-bromazepam Tabletstablet3 mgoralPentapharm Ltd.1999-07-132004-07-30Canada
Penta-bromazepam Tabletstablet6 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Riva-bromazepam 3 mgtablet3 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-bromazepam 6 mgtablet6 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Teva-bromazepamtablet3 mgoralTeva Canada Limited1997-03-03Not applicableCanada
Teva-bromazepamtablet6 mgoralTeva Canada Limited1997-03-03Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bromazepam - Tab 1.5mgtablet1.5 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-bromazepam - Tab 3mgtablet3 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-bromazepam - Tab 6mgtablet6 mgoralApotex Inc1995-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CalmepamNot Available
CreosedinNot Available
DurazanilNot Available
LectopamNot Available
LekotamNot Available
LexaurinNot Available
LexiliumNot Available
LexomilNot Available
LexotanNot Available
NormocNot Available
UltramidolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX015L14V0O
CAS number1812-30-2
WeightAverage: 316.153
Monoisotopic: 315.000724604
Chemical FormulaC14H10BrN3O
InChI KeyInChIKey=VMIYHDSEFNYJSL-UHFFFAOYSA-N
InChI
InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
IUPAC Name
7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Bromobenzene
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
PharmacodynamicsBromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Mechanism of actionBromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.
Related Articles
AbsorptionBioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.
Volume of distribution

1.56 L/kg

Protein binding70%
Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

Route of eliminationUrine (69%), as metabolites
Half life10-20 hours
Clearance

0.82 mL/min/kg.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.9848
Caco-2 permeable+0.7571
P-glycoprotein substrateSubstrate0.5741
P-glycoprotein inhibitor INon-inhibitor0.7251
P-glycoprotein inhibitor IINon-inhibitor0.924
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.8385
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7117
CYP450 1A2 substrateInhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.8511
CYP450 2C19 inhibitorNon-inhibitor0.5719
CYP450 3A4 inhibitorNon-inhibitor0.7405
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6441
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8704
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9974
hERG inhibition (predictor II)Non-inhibitor0.7977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1.5 mg
Tabletoral3 mg
Tabletoral6 mg
Prices
Unit descriptionCostUnit
Lectopam 6 mg Tablet0.25USD tablet
Lectopam 3 mg Tablet0.17USD tablet
Apo-Bromazepam 6 mg Tablet0.13USD tablet
Gen-Bromazepam 6 mg Tablet0.13USD tablet
Novo-Bromazepam 6 mg Tablet0.13USD tablet
Apo-Bromazepam 3 mg Tablet0.09USD tablet
Gen-Bromazepam 3 mg Tablet0.09USD tablet
Novo-Bromazepam 3 mg Tablet0.09USD tablet
Apo-Bromazepam 1.5 mg Tablet0.07USD tablet
Gen-Bromazepam 1.5 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0399 mg/mLALOGPS
logP2.09ALOGPS
logP2.54ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.24ChemAxon
pKa (Strongest Basic)2.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.35 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity76.99 m3·mol-1ChemAxon
Polarizability28.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00n0-9463000000-abe7fdab778f08fe18c4View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  2. Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [PubMed:14517708 ]
  3. van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [PubMed:8846617 ]
  4. Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [PubMed:2882883 ]
External Links
ATC CodesN05BA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Bromazepam can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Bromazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bromazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bromazepam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam.
AminophyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Bromazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam.
AmoxapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amperozide.
AprepitantThe serum concentration of Bromazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.
ArmodafinilThe metabolism of Bromazepam can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Asenapine.
AtazanavirThe metabolism of Bromazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azaperone.
AzelastineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bromazepam.
AzithromycinThe metabolism of Bromazepam can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Bromazepam.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Bromazepam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Bromazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Bromazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Bromazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bromazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brimonidine.
BrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bromazepam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam.
ButacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Bromazepam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.
CaffeineThe metabolism of Bromazepam can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Bromazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bromazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Bromazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Bromazepam can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Bromazepam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Bromazepam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromazepam.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Bromazepam can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Bromazepam can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromazepam.
CitalopramThe risk or severity of adverse effects can be increased when Bromazepam is combined with Citalopram.
CitalopramThe metabolism of Bromazepam can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Bromazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.
ClotrimazoleThe metabolism of Bromazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Bromazepam.
CobicistatThe metabolism of Bromazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Bromazepam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam.
ConivaptanThe serum concentration of Bromazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Bromazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.
CyclosporineThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Bromazepam can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine.
DarunavirThe metabolism of Bromazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Bromazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Bromazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Bromazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam.
DesipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Bromazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bromazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bromazepam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bromazepam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bromazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Bromazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.
DihydroergotamineThe metabolism of Bromazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bromazepam.
DihydromorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.
DiltiazemThe metabolism of Bromazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam.
DoramectinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.
DoxycyclineThe metabolism of Bromazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Bromazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
DronedaroneThe metabolism of Bromazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Bromazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Bromazepam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam.
DyphyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Bromazepam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Bromazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Bromazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Bromazepam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Bromazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Bromazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Bromazepam can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Bromazepam can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Bromazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam.
EthanolBromazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Bromazepam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bromazepam.
EtidocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bromazepam.
EtravirineThe serum concentration of Bromazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Bromazepam.
FenfluramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.
FluconazoleThe metabolism of Bromazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Bromazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluoxetine.
FluoxetineThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Bromazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Bromazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bromazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bromazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Bromazepam.
FospropofolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Bromazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Bromazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Bromazepam.
GemfibrozilThe metabolism of Bromazepam can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Bromazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Bromazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Bromazepam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bromazepam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Bromazepam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bromazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Bromazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.
ImatinibThe metabolism of Bromazepam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.
IndinavirThe metabolism of Bromazepam can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Bromazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bromazepam.
IsoniazidThe metabolism of Bromazepam can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Bromazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Bromazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Bromazepam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.
KetazolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Bromazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bromazepam.
LevocabastineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bromazepam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam.
LidocaineThe metabolism of Bromazepam can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Bromazepam.
LofentanilThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lofentanil.
LopinavirThe metabolism of Bromazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam.
LovastatinThe metabolism of Bromazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Bromazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Bromazepam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bromazepam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Bromazepam.
MelperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromazepam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromazepam.
MetaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.
MethadoneBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bromazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bromazepam.
MethapyrileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Bromazepam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Bromazepam.
MethsuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Bromazepam.
MetyrosineBromazepam may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Bromazepam can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.
MifepristoneThe metabolism of Bromazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
MirtazapineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bromazepam.
MitotaneThe serum concentration of Bromazepam can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Bromazepam can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Bromazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
NabiloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nabilone.
NafcillinThe serum concentration of Bromazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam.
NefazodoneThe metabolism of Bromazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Bromazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Bromazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Bromazepam can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Bromazepam can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Bromazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.
OlaparibThe metabolism of Bromazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.
OmeprazoleThe metabolism of Bromazepam can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Bromazepam.
OpiumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Opium.
OrphenadrineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bromazepam.
OsanetantThe risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.
OsimertinibThe serum concentration of Bromazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam.
OxprenololThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Bromazepam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam.
PalbociclibThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.
PantoprazoleThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.
ParaldehydeBromazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Bromazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Bromazepam.
PerampanelThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bromazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bromazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Bromazepam.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam.
PipamperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Bromazepam can be decreased when combined with Posaconazole.
PramipexoleBromazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Bromazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Bromazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.
PromethazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Bromazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Bromazepam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.
RamelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon.
RanolazineThe metabolism of Bromazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam.
RifabutinThe metabolism of Bromazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Bromazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Bromazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.
RitonavirThe metabolism of Bromazepam can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Romifidine.
RopiniroleBromazepam may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Bromazepam can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam.
RotigotineBromazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Bromazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Bromazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Bromazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.
SertindoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertraline.
SertralineThe metabolism of Bromazepam can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.
SildenafilThe metabolism of Bromazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Bromazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bromazepam can be increased when it is combined with Simeprevir.
Sodium oxybateBromazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Bromazepam.
St. John's WortThe serum concentration of Bromazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.
SulfisoxazoleThe metabolism of Bromazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Bromazepam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tasimelteon.
TeduglutideThe serum concentration of Bromazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Bromazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Bromazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam.
TenofovirThe metabolism of Bromazepam can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrodotoxin.
ThalidomideBromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bromazepam.
TheophyllineThe metabolism of Bromazepam can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromazepam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Bromazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine.
TiclopidineThe metabolism of Bromazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromazepam.
TrimipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Bromazepam.
VemurafenibThe serum concentration of Bromazepam can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Bromazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Bromazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Bromazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.
ZiconotideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Bromazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Bromazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Bromazepam.
ZotepineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23